| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025010 |
| Receipt No. | R000028775 |
| Scientific Title | Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study) |
| Date of disclosure of the study information | 2016/12/01 |
| Last modified on | 2021/09/02 (Ver. 7) |
| Basic information | ||
| Public title | Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study) | |
| Acronym | Trimodality with Adjuvant Radiation in Stage N2-3A/3B Non-small Cell Lung Cancer | |
| Scientific Title | Induction Chemotherapy and Adjuvant Thoracic Radiation in Resectable Stage N2-3A/3B Non-small Cell Lung Cancer (ICAT study) | |
| Scientific Title:Acronym | Trimodality with Adjuvant Radiation in Stage N2-3A/3B Non-small Cell Lung Cancer | |
| Region |
|
|
| Condition | |||
| Condition | Resectable Stage 3A-N2 Non-small Cell Lung Cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To clarify the feasibility of trimodality treatment with induction chemotherapy, radical surgery, and adjuvant radiation in stage 3A-N2 non-small cell lung cancer |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | feasibility |
| Key secondary outcomes | response rate of induction chemotherapy, safety, progression free survival |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Trimodality treatment with 3 course of induction chemotherapy with Carboplatin AUC5 and nab-Paclitaxel 100mg/m2, radical surgery more than lobectomy, adjuvant radiation 50Gy | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Stage 3A non-small-cell lung cancer (NSCLC) with mediastinal lymph node metastasis (N2) confirmed pathologically without chest wall invasion
2.R0 radical surgery is expected after induction chemotherapy 3.Normal pulmonary function (%VC > 80%, FEV1% > 70%) within 56 days prior to consent 4.Chemotherapy-naive and radiotherapy-naive 5.20 - 75 years of age at enrollment 6.ECOG Performance Status 0-1 7.The latest clinical laboratory test within 28 days prior to enrollment meets the following all standard Leukocyte count > 3,000/mm3 Hemoglobin > 10.0g/dl Platelet > 100,000/mm3 Total bilirubin < 1.5mg/dl Serum albumin > 3.0g/dl AST/ALT < 100 IU Creatinine < 1.2mg/dl SpO2 > 95% 8.Patients providing the written informed consent for this trial |
|||
| Key exclusion criteria | 1.Evident unresectable extranodal lymph node involvement in CT scanning
2.Contraindication to either carboplatin or nab-paclitaxel 3.History of severe drug hypersensitivity 4.Impaired pulmonary function 5.Myocardial infarction within 6 months (180 days) prior to consent 6.Interstitial pneumonia, pulmonary fibrosis suspected or diagnosed within 56 days prior to consent 7.Administration of prednisolone > 10mg/day within 90 days prior to consent 8.Clinically severe heart diseases 9.Clinically severe psychiatric diseases 10.Uncontrollable diabetes mellitus 11.Clinically active infection 12.Any other severe complication 13.Active double malignancies 14.Pregnant, lactating or possibly pregnant 15.Any other unsuitable reasons judged by attending investigators |
|||
| Target sample size | 25 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Division of Thoracic Surgery, Department of Surgery | ||||||
| Zip code | 6028566 | ||||||
| Address | Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto | ||||||
| TEL | +81752515739 | ||||||
| mainoue@koto.kpu-m.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kyoto Prefectural University of Medicine | ||||||
| Division name | Division of Thoracic Surgery, Department of Surgery | ||||||
| Zip code | 6028566 | ||||||
| Address | Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto | ||||||
| TEL | 075-251-5739 | ||||||
| Homepage URL | |||||||
| tsune@koto.kpu-m.ac.jp | |||||||
| Sponsor | |
| Institute | Kyoto Prefectural University of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kyoto Prefectural University of Medicine
Division of Thoracic Surgery, Department of Surgery |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Kyoto Prefectural University of Medicine
The Center for Quality Assurance in Research and Development |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyoto Prefectural University of Medicine, IRB |
| Address | Kajii-cho 465, Kawaramachi-Hirokoji, Kamigyo-Ku ,Kyoto |
| Tel | 0752515337 |
| rinri@koto.kpu-m.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 1 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028775 |